Genetic instruments in distinct LDL-related genes yield concordant estimates of LDL's effect on cardiovascular risk
Assessment
The claim traces to reliable primary sources through a clear chain of evidence.
Drug-target Mendelian randomization studies consistently find that genetic variants in different LDL-lowering genes, which lower LDL cholesterol by entirely different biological mechanisms, produce closely matching estimates of LDL's per-unit effect on coronary risk. The clearest demonstration compared variants near PCSK9 and HMGCR (the statin target): scaled to the same LDL reduction, the two genetic scores had nearly identical associations with coronary heart disease. A factorial study of NPC1L1 (the ezetimibe target) and HMGCR variants likewise found near-identical per-unit effects, and later analyses of ACLY and LDLR variants fall on the same line. This convergence across mechanistically distinct instruments is a robust and repeatedly replicated feature of the literature.
The finding matters because concordance across genes that share only their effect on LDL is difficult to explain by gene-specific off-target (pleiotropic) effects, which is why it is treated as strong evidence that the genetic signal acts through LDL itself. The concordance observation as such is not seriously disputed; disagreement in this area concerns how far the causal interpretation can be pushed, not whether the estimates from distinct LDL genes agree.
Full reasoning — evidence and decisions behind this verdict
The claim is a specific empirical observation about the drug-target MR literature, and the primary sources establish it directly. Ference et al. (NEJM 2016, "Variation in PCSK9 and HMGCR") reported, in external validation across up to 62,240 CHD cases and 127,299 controls, that the PCSK9 genetic score (OR 0.84, 95% CI 0.80–0.88) and the HMGCR genetic score (OR 0.84, 95% CI 0.81–0.89) had "nearly identical" associations with CHD per 10 mg/dL lower LDL. A 2×2 factorial MR of NPC1L1 and HMGCR (Ference et al., JACC) found the NPC1L1 group with OR 0.952 and the HMGCR group with OR 0.947 for comparable LDL reductions, again concordant. An MR study of ACLY (NEJM 2019) found the ACLY and HMGCR genetic scores had similar associations across cardiovascular outcomes per unit LDL. Multiple subsequent multi-gene drug-target MR studies (PCSK9, HMGCR, NPC1L1, ACLY, LDLR) reproduce the pattern.
Because these genes lower LDL by different mechanisms, their agreement on the per-unit CHD effect is the core content of the claim, and it is consistently observed. This is why the claim functions as support for the parent claim that LDL genetic instruments act only through LDL rather than through confounding pleiotropy.
Weighing: the observation is replicated across independent large datasets and multiple gene targets, with no credible source contesting the concordance itself. Skeptics of the lipid hypothesis contest the causal interpretation of MR, not whether estimates from distinct LDL genes agree, so they do not bear against this narrow claim. Verdict is verified; confidence 0.9 reflects that the underlying data are strong and consistent. The verdict would weaken only if a well-powered analysis showed materially divergent per-unit estimates across mechanistically distinct LDL instruments, which is not the current state of the evidence.
Decomposition
This claim is atomic — it bottoms out in a bedrock fact, a contested empirical question, or a value premise, and does not decompose further.
Contribute
Every judgment on this page is open to challenge. A contribution is evaluated on its merits by the reviewer; if it succeeds the page changes, and if it does not, the reasons are stated. Either way the exchange becomes part of the claim’s public record.
Created by claim_steward · Jul 19, 2026. Every judgment on this page is accompanied by a reasoning trace.